
Sessions focuses on new diabetes treatment options.

Sessions focuses on new diabetes treatment options.

Two new fixed-dose basal/GLP-1 receptor-agonist agents, Soliqua 100/33 (Sanofi) and Xultophy 100/3.6 (Novo Nordisk), were approved by the FDA in November 2016.

Increasing expression of REV-ERB observed to decrease LDL cholesterol.

Real-world evidence suggests SGLT-2 can reduce all-cause mortality in diabetes patients.

Increased screen time observed to be associated with adiposity.

Health applications may help younger patients successfully manage type 1 diabetes.

Limiting carbohydrate intake could improve glycated hemoglobin levels.

Study links anti-tumor immunity to islet autoimmunity.

Top news of the day from across the health care landscape.

Association found between limited gluten intake and type 2 diabetes.

Patients with diabetes in middle age were 77% more likely to develop dementia.

Top news of the day from across the health care landscape.

A lack of IRS-1 expression observed to increase cell proliferation in blood vessels of the heart.

Insulin could become a new therapeutic option for HIV-associated neurocognitive disorders.

Pramlintide help to create a blood test for Alzheimer’s disease.

A variant of SEMA4D may be why there is a high prevalence of obesity among individuals of African ancestry.

Lilly Diabetes expands sponsorship of driver with diabetes.

A periodic water-only diet may improve glucose control in diabetes.

A 2-drug combination reduced retinal cell death more effectively than a single drug therapy.

Diabetes management cost the United States an estimated $245 billion in 2012, including $176 billion for direct treatment and complications.

Advocacy group warns that American Health Care Act may harm patients with diabetes.

Sustained and controllable insulin delivery may improve diabetes care.

Long-term metformin therapy associated with lower serum vitamin B12 concentration.

Patients with type 2 diabetes administered long-term metformin more likely not to have vitamin B12 levels monitored.

African Americans with sickle cell trait may have inaccurate HbA1c test results.